Trial Profile
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of PROCHYMAL (Ex Vivo Cultured Adult Human Mesenchymal Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Dec 2021
Price :
$35
*
At a glance
- Drugs Remestemcel-L (Primary)
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Osiris Therapeutics
- 03 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 20 May 2014 New trial record
- 15 Jan 2010